DexCom Faces Short-Term Challenges, But Market Growth Prospects Remain Strong-Analyst
DexCom Faces Short-Term Challenges, But Market Growth Prospects Remain Strong-Analyst
DexCom Inc (NASDAQ:DXCM) reported second-quarter sales of more than $1 billion. That's up 15% year-over-year on a reported basis and 16% on an organic basis.
德克斯康公司（纳斯达克股票代码：DXCM）报告称，第二季度销售额超过10亿美元。根据报告，同比增长15％，有机增长16％。
The glucose monitoring device maker reported a second-quarter adjusted EPS of 43 cents. That's up from 34 cents a year ago, beating the consensus of 39 cents.
这家血糖监测设备制造商报告称，第二季度调整后的每股收益为43美分。这比去年同期的34美分有所上涨，超过了共识的39美分。
The company expects 2024 sales of $4.00 billion—$4.05 billion (11 – 13% organic growth), down from prior guidance of $4.20 billion—$4.35 billion versus a consensus of $4.33 billion.
该公司预计，2024年的销售额为40.0亿美元至40.5亿美元（11％至13％的有机增长），低于之前预期的42.0亿美元至43.5亿美元，而市场普遍预期为43.3亿美元。
Related: FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's.
相关信息：分析师预计，美国食品药品管理局批准DexCom的Stelo向大众开放了持续的血糖监测，其定价将与雅培相比具有竞争力。
William Blair writes that "the bigger surprise was that management decreased guidance by $200million-$300 million for the full year. This change we believe has led investors to question the longer-term growth profile for DexCom, and ultimately led to the stock being indicated down."
威廉·布莱尔写道：“更令人惊讶的是，管理层将全年预期下调了2亿至3亿美元。我们认为，这一变化使投资者质疑DexCom的长期增长前景，并最终导致该股下跌。”
"We remain believers in the story given our view of the market outlook and DexCom's strong product portfolio and ecosystem. We believe the reasons for the miss and guide down are (painfully) self-inflicted, though ultimately, should prove transient and manageable. As a result, we maintain our Outperform rating," the analyst adds.
“鉴于我们对市场前景的看法以及DexCom强大的产品组合和生态系统，我们仍然坚信这个故事。我们认为，失误和失误的原因是（痛苦地）自己造成的，尽管归根结底应该是短暂的，也是可以控制的。因此，我们维持了跑赢大盘的评级。” 分析师补充说。
William Blair anticipates domestic continuous glucose monitoring market growth in the high teens through 2027. The firm also expects potential for mid-20% growth in a bull case.
威廉·布莱尔预计，到2027年，国内持续血糖监测市场将在十几岁之前增长。该公司还预计，牛市可能实现-20％的增长。
The analyst says DexCom can expand the market through increased coverage and reclaim recent market share losses by improving its pharmacy channel expansion and re-engaging the DME channel.
这位分析师表示，DexCom可以通过扩大覆盖范围来扩大市场，并通过改善药房渠道扩张和重新参与DME渠道来弥补最近的市场份额损失。
These short-term issues are expected to be temporary. William Blair foresees significant growth potential in intensive insulin users.
这些短期问题预计将是暂时的。威廉·布莱尔预计，胰岛素密集使用者的增长潜力巨大。
Price Action: DXCM stock is down 40% at $64.78 at last check Friday.
价格走势：周五最后一次检查时，DxCM股价下跌40％，至64.78美元。
- Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events.
- Biogen/Eisai的阿尔茨海默氏症药物Leqembi援引严重的附带事件，被欧洲药品监管机构咨询小组的 “拒绝”。